MHC-II neoantigens shape tumour immunity and response to immunotherapy.

ABSTRACT: The ability of the immune system to eliminate and shape the immunogenicity of tumours defines the process of cancer immunoediting¹. Immunotherapies such as those that target immune checkpoint molecules can be used to augment immune-mediated elimination of tumours and have resulted in durable responses in patients with cancer that did not respond to previous treatments. However, only a subset of patients benefit from immunotherapy and more knowledge about what is required for successful treatment is needed^2-4. Although the role of tumour neoantigen-specific CD8⁺ T cells in tumour rejection is well established^5-9, the roles of other subsets of T cells have received less attention. Here we show that spontaneous and immunotherapy-induced anti-tumour

SUBMITTER: Alspach E 

PROVIDER: S-EPMC6858572 | biostudies-literature | 2019 Oct

REPOSITORIES: biostudies-literature